We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Advanced Oncotherapy Plc | LSE:AVO | London | Ordinary Share | GB00BD6SX109 | ORD 25P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 1.925 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Medical Laboratories | 0 | -29.49M | -0.0549 | -0.35 | 10.32M |
From Apr 2019 to Apr 2024
TIDMAVO
RNS Number : 8033Q
Advanced Oncotherapy PLC
22 February 2019
22 February 2019
ADVANCED ONCOTHERAPY PLC
("Advanced Oncotherapy" or the "Company")
Grant of Options and 2018 SAYE Option Plan
Advanced Oncotherapy plc (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that its Remuneration Committee has approved the grant of share options (the "Options") over a total of 4,000,000 new ordinary shares of 25 pence each ("Ordinary Shares").
Of the Options, 545,000 have been granted to Dr Michael Sinclair (Executive Chairman), 1,400,000 to Nicolas Serandour (Chief Executive Officer), 215,000 to Professor Stephen Myers (Non-Executive Director of Advanced Oncotherapy and Executive Chairman of ADAM) and the remaining 1,840,000 to members of key management, including a PDMR.
The Options have been granted at an exercise price of 100 pence per share (implying a 141% premium over the closing share price on 20 February 2019). The options have a five-year term, expiring on 20 February 2024. This Option grant is consistent with the Remuneration Committee's policy to align the interests of key personnel and shareholders through appropriate incentive schemes, including the award of shares and share options. It follows recent achievements, including the recent ISO:13485 certification, the significant progress on the LIGHT system which generates a beam with an energy level capable of treating superficial tumours and the GBP10 million funding round announced on 21 December 2018.
Separately, pursuant to the Company's 2018 SAYE Option Plan and further to the announcement released on 21 December 2018, the Board has granted options over a total of 1,449,342 new Ordinary Shares (the "SAYE Options"). A total of 66 employees elected to participate in the 2018 SAYE Option Plan, including one employee who is classified as a PDMR.
The SAYE Options have been granted at a price of 40 pence per share which is equivalent to the price of the GBP10 million funding round announced in December 2018. The SAYE Options have a savings contract start date of 1 March 2019 and are exercisable between 1 March 2022 and 31 August 2022.
Following the grant of the Options and the SAYE Options, the Company has options outstanding over 10,616,011 new Ordinary Shares, which represents approximately 5.46 per cent. of the Company's issued ordinary share capital.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
Hot Features
Premium
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Michael Sinclair (Director)
Nicolas Serandour (Director)
Steve Myers (Director)
Ed Lee (PDMR)
Bérengère Pons-Chabord
(PDMR)
-------------------------------- ------------------------------------------------------
2 Reason for the notification
----------------------------------------------------------------------------------------
a) Position/status See 1 a) above
-------------------------------- ------------------------------------------------------
b) Initial notification /Amendment Initial notification
-------------------------------- ------------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
----------------------------------------------------------------------------------------
a) Name Advanced Oncotherapy plc
-------------------------------- ------------------------------------------------------
b) LEI 213800LUDHZOG3YT6C82
-------------------------------- ------------------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
----------------------------------------------------------------------------------------
a) Description of the financial Ordinary shares of 25p each in Advanced
instrument, type of instrument Oncotherapy plc
Identification code
Identification code (ISIN) for Advanced
Oncotherapy plc ordinary shares:
GB00BD6SX109
-------------------------------- ------------------------------------------------------
b) Nature of the transaction Grant of options over new ordinary
shares
-------------------------------- ------------------------------------------------------
c) Price(s) and volume(s) PDMR Price(s) Volume(s)
Michael Sinclair (Director)
Nicolas Serandour 100p 545,000
(Director)
100p 1,400,000
Steve Myers (Director)
100p 215,000
Ed Lee (PDMR)
100p 215,000
Bérengère
Pons-Chabord (PDMR) 100p 140,000
--------- -----------
-------------------------------- ------------------------------------------------------
d) Aggregated information Price(s) Volume(s)
- Aggregated volume 100p 2,515,000
- Price ----------
-------------------------------- ------------------------------------------------------
e) Date of the transaction 21 February 2019
-------------------------------- ------------------------------------------------------
f) Place of the transaction outside of a trading venue - grant
of options
-------------------------------- ------------------------------------------------------
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Bérengère Pons-Chabord
-------------------------------- -----------------------------------------
2 Reason for the notification
---------------------------------------------------------------------------
a) Position/status PDMRs
-------------------------------- -----------------------------------------
b) Initial notification /Amendment Initial notification
-------------------------------- -----------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
---------------------------------------------------------------------------
a) Name Advanced Oncotherapy plc
-------------------------------- -----------------------------------------
b) LEI 213800LUDHZOG3YT6C82
-------------------------------- -----------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
---------------------------------------------------------------------------
a) Description of the financial Ordinary shares of 25p each in Advanced
instrument, type of instrument Oncotherapy plc
Identification code
Identification code (ISIN) for Advanced
Oncotherapy plc ordinary shares:
GB00BD6SX109
-------------------------------- -----------------------------------------
b) Nature of the transaction Grant of SAYE options over new ordinary
shares
-------------------------------- -----------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
40p 45,000
----------
-------------------------------- -----------------------------------------
d) Aggregated information n/a
- Aggregated volume
- Price
-------------------------------- -----------------------------------------
e) Date of the transaction 21 February 2019
-------------------------------- -----------------------------------------
f) Place of the transaction outside of a trading venue - grant
of SAYE options
-------------------------------- -----------------------------------------
For further information, please contact:
Advanced Oncotherapy Plc Tel: +44 (0) 20 3617 8728
Dr. Michael Sinclair, Executive www.avoplc.com
Chairman
Nicolas Serandour, CEO
Allenby Capital Limited (Nominated Tel: +44 (0) 20 3328 5656
Adviser & Joint Broker)
Nick Athanas / Liz Kirchner /
Nicholas Chambers
Stifel Nicolaus Europe (Joint Tel: +44 (0) 20 7710 7600
Broker)
Jonathan Senior
Walbrook PR (Financial PR & IR) Tel: +44 (0) 20 7933 8780 avo@walbrookpr.com
Paul McManus / Anna Dunphy Mob: +44 (0) 7980 541 893
Mob: +44 (0) 7876 741 001
About Advanced Oncotherapy Plc www.avoplc.com
Advanced Oncotherapy is a provider of particle therapy in the treatment of cancer, which harnesses the very best in modern technology. Advanced Oncotherapy's R&D team, ADAM, in Geneva, focuses on the development of a proprietary proton accelerator - LIGHT (Linac Image Guided Hadron Technology). LIGHT accelerates protons to the energy levels achieved in legacy machines but in a compact and truly modular unit, offering significant cost advantages. LIGHT also delivers proton beams in a way that facilitates greater precision and electronic control, which are not achievable with currently available alternative technologies.
Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology, offering better health outcomes and lower treatment related side effects.
Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton or particle therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of cutting edge, cost-effective systems for particle therapy.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
DSHDBGDDLGDBGCB
(END) Dow Jones Newswires
February 22, 2019 02:00 ET (07:00 GMT)
1 Year Advanced Oncotherapy Chart |
1 Month Advanced Oncotherapy Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
